Clinical Trial

KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The main purpse of this study is to evaluate the safety of KSD-101 in patients with EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated Nasopharyngeal Carcinoma.
Trial Details
NCT Number NCT06752473
Lead Sponsor Kousai Bio Co., Ltd.
Conditions Nasopharyngeal Carcinoma (NPC), EBV
Enrollment 10 participants
Start Date 2025-01-31
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-12-30